News from nektar therapeutics

Jun 19, 2014, 15:29 ET

Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients

Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published...

Jun 12, 2014, 16:15 ET

US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA)...

Jun 11, 2014, 07:05 ET

Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists

Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has...

Jun 01, 2014, 09:00 ET

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

 Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which...

May 31, 2014, 14:15 ET

Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting

Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in...

May 19, 2014, 08:00 ET

Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer

 Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel,...

May 16, 2014, 22:22 ET

Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City

 Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton...

May 07, 2014, 16:15 ET

Nektar Therapeutics Reports Financial Results for the First Quarter of 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2014. Cash and investments in...

May 01, 2014, 16:10 ET

Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014,...

Apr 09, 2014, 09:00 ET

Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR

 Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer...

Feb 26, 2014, 16:15 ET

Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013. Cash and...

Feb 19, 2014, 16:15 ET

Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday,...

Jan 22, 2014, 21:59 ET

Nektar Therapeutics Prices Public Offering of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of 8,500,000...

Jan 21, 2014, 16:10 ET

Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced that it has commenced an underwritten public offering of 8,500,000 shares of its...

Jan 18, 2014, 12:00 ET

Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium

Nektar Therapeutics' (Nasdaq: NKTR) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with...

Jan 14, 2014, 08:15 ET

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

 Nektar Therapeutics (NASDAQ:NKTR) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for...

Jan 14, 2014, 08:00 ET

First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain

Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new...

Jan 08, 2014, 17:38 ET

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 32nd...

Nov 19, 2013, 07:00 ET

New Drug Application For Naloxegol Accepted By United States Food And Drug Administration

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA)...

Nov 13, 2013, 09:34 ET

Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A

 Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer